Literature DB >> 15974578

Positional effect of chemical modifications on short interference RNA activity in mammalian cells.

Thazha P Prakash1, Charles R Allerson, Prasad Dande, Timothy A Vickers, Namir Sioufi, Russell Jarres, Brenda F Baker, Eric E Swayze, Richard H Griffey, Balkrishen Bhat.   

Abstract

A systematic study on the effect of 2'-sugar modifications (2'-F (2'-F-2'-deoxy-nucleoside residues), 2'-O-Me (2'-O-methyl-nucleoside residues), and 2'-O-MOE [2'-O-(2-methoxyethyl)]-nucleoside residues) in the antisense and sense strands of short interference RNA (siRNA) was performed in HeLa cells. The study of the antisense strand of siRNAs demonstrated that activity depends on the position of the modifications in the sequence. The siRNAs with modified ribonucleotides at the 5'-end of the antisense strand were less active relative to the 3'-modified ones. The 2'-F sugar was generally well-tolerated on the antisense strand, whereas the 2'-O-Me showed significant shift in activity depending on the position of modification. The 2'-O-MOE modification in the antisense strand resulted in less active siRNA constructs regardless of placement position in the construct. The incorporation of the modified residues, e.g., 2'-O-Me and 2'-O-MOE, in the sense strand of siRNA did not show a strong positional preference. These results may provide guidelines to design effective and stable siRNAs for RNA interference mediated therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15974578     DOI: 10.1021/jm050044o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  84 in total

1.  Synthetic CRISPR RNA-Cas9-guided genome editing in human cells.

Authors:  Meghdad Rahdar; Moira A McMahon; Thazha P Prakash; Eric E Swayze; C Frank Bennett; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

Review 2.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

Review 3.  Ligand-targeted delivery of therapeutic siRNA.

Authors:  Yutaka Ikeda; Kazunari Taira
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 4.  Chemical modification: the key to clinical application of RNA interference?

Authors:  David R Corey
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA.

Authors:  Katarzyna Sipa; Elzbieta Sochacka; Julia Kazmierczak-Baranska; Maria Maszewska; Magdalena Janicka; Genowefa Nowak; Barbara Nawrot
Journal:  RNA       Date:  2007-06-21       Impact factor: 4.942

6.  Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.

Authors:  Michael A Collingwood; Scott D Rose; Lingyan Huang; Chris Hillier; Mohammad Amarzguioui; Merete T Wiiger; Harris S Soifer; John J Rossi; Mark A Behlke
Journal:  Oligonucleotides       Date:  2008-06

7.  Promiscuous 8-alkoxyadenosines in the guide strand of an siRNA: modulation of silencing efficacy and off-pathway protein binding.

Authors:  Uday Ghanty; Erik Fostvedt; Rachel Valenzuela; Peter A Beal; Cynthia J Burrows
Journal:  J Am Chem Soc       Date:  2012-10-11       Impact factor: 15.419

Review 8.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

9.  Effect of 2'-5'/3'-5' phosphodiester linkage heterogeneity on RNA interference.

Authors:  Maryam Habibian; S Harikrishna; Johans Fakhoury; Maria Barton; Eman A Ageely; Regina Cencic; Hassan H Fakih; Adam Katolik; Mayumi Takahashi; John Rossi; Jerry Pelletier; Keith T Gagnon; P I Pradeepkumar; Masad J Damha
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971

10.  Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis.

Authors:  Virender Kumar; Vinod Kumar; Jiangtao Luo; Ram I Mahato
Journal:  Mol Ther       Date:  2018-09-01       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.